In an updated analysis of the same cohort with additional 3115 women and 199 cases, Schrijver et al., reported a significantly reduced risk of ovarian cancer for formulations initiated pre-1975 (HR = 0.57, 95% CI 0.44–0.75) and a suggestively reduced risk for formulations initiated post-1975 compared to never use (HR = 0.77, 95% CI 0.54–1.09) for BRCA1 mutation carriers [34]. Here, BRCA1 is linked to ovarian carcinoma.